ΔΗΜΟΣΙΕΥΣΕΙΣ 1. Mimidis K., Tsatalas C., Margaritis D., Martinis G., Spanoudakis E., Kotsiou S., Kartalis G., Bourikas G. Efficacy of Lamivudine in patients with hematologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B.ActaHaematol. 2002;107(1):49-51. 2.Tsatalas C, Martinis G., D. Margaritis, E. Spanoudakis, I. Kotsianidis, A. Karpouzis, G. Bourikas. Long-term remission of recalcitrant tumour-stage mycosis fungoides following chemotherapy with pegylated liposomal doxorubicin. J EurAcadDermatolVenereol. 2003 Jan;17(1):80-2. 3.Tsatalas C., Margaritis D., Pantelidou D., Spanoudakis E., Kaloutsi V., Bourikas G.Treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T- cell lymphoma with fludarabine.ActaHaematol. 2003;109(2):110. 4. C. Tsatalas, D. Margaritis, D. Pantelidou, I. Kotsianidis, A.J. Karayannakis, E. Spanoudakis, Z. Kartasis, V. Kaloutsi, A. Polychronidis, I. Manavis, G. Bourikas. Splenectomy for massive splenic infarction unmasks paroxysmal nocturnal hemoglobinuria. ActaHaematol 2003;110(4):193-95. 5. K. Mimidis, V. Papadopoulos, I. Kotsianidis, D. Filippou, E. Spanoudakis, G. Bourikas, C. Dervenis, G. Kartalis. Αlterations of platelet function, number and indexes during acute pancreatitis.Pancreatology2004;4(1):22-7. 6.C. Tsatalas, E. Spanoudakis, D. Pantelidou, D. Margaritis, I.Kotsianidis, P. Chalkia, G. Tripsianis, I. Basdiara, Z. Kartasis, A. Karakolios, G.Bourikas. AmifostineStimulatesTheFormationOfHaematopoieticBoneMarrowProgenitorsFromB- cellChronicLymphocyticLeukemia (B-CLL).ActaHaematol. 2004;112(3):136-40. 7. Pantelidou D., Tsatalas C., Margaritis D., Kaloutsi V., Spanoudakis E., Bourikas G.Anti-CD20 monoclonalantibodyrituximabforthetreatmentofB- cellchroniclymphocyticleukemia- associatedpureredcellaplasia.Heamatol.J.2004;5(6):546-7. 8. Pantelidou D., Tsatalas C., Margaritis D., Karayiannakis AJ., Kaloutsi V., Spanoudakis E., Katsileris I., Chatzipaschalis E., Sivridis E., Bourikas G. Extramedullaryplasmacytoma: report of two cases with uncommon presentation. Ann. Hematol. 2005 Mar;84(3):188- 91. 9.Ioannis Kotsianidis, Jonathan D. Silk, Emmanouil Spanoudakis, Scott Patterson, Antonio Almeida, Richard R. Schmidt, Costas Tsatalas, George Bourikas, Vincenzo Cerundolo, Irene A. G. Roberts, and Anastasios Karadimitris Regulation of hematopoiesis in vitro and in vivo by invariant NKT cells. Blood, 15 April 2006, Vol. 107, No. 8, pp. 3138-3144. 10.AnastasiosKaradimitris, Scott Patterson, Emmanouil Spanoudakis. NKT and Haemopoiesis. Review article. British Journal of Haematology. 2006. Aug; 134(3): 105-10. 11.Matsouka P., Pagoni M., Zikos P., Giannakoulas N., Apostolidis I., Asprogeraka T., Arvanitopoulou E., Spanoudakis E., Kotsianidis I., Tsatalas C., Papaioannou M., Marinakis G., Megalakakis A., Skandala., Viniou N., Yataganas X., Bakiri M. Additionofcyclosporin-Atochemotherapyinsecondary (post-MDS) AMLintheelderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology. AnnHematol. 2006 Apr;85(4):250-6. 12.Stakos DA., Kotsianidis I., Tziakas D., Spanoudakis E.,Chalkias G., Bourikas G., Katsaris G., Boudoulas H. Leukocyte activation after coronary stenting in patients during the subacute phase of a previous ST-elevation myocardial infarction. Coron Art Disease Mar 2007; 18(2): 105-110. 13. E. Spanoudakis, D. Margaritis, I. Kotsianidis, G. Georgiou G. Tripsianis, A. Anastasiadis,A. Karakolios, D. Pantelidou, P. Panayiotidis, G. Bourikas, C. Tsatalas.Long Term Bone Marrow Cultures (LTBMC) from Essential Thrombocythemia (ET) patients with or without JAK2617V>F mutation. Leukemia Research, March 2008.(32); 1593-1596. 14. I.Kotsianidis, I. Basdiara, Α. Anastasiades, E. Spanoudakis, D. Pantelidou, D. Margaritis, G.Bourikas, De Coster R., De Porre P.,C. Tsatalas. In-vitro effects of farnesyltransferase inhibitor Tipifarnib on Myelodysplastic syndrome progenitors. ActaHaematologica 2008;120(1):51-56. 15.Emmanouil Spanoudakis, IoannaBazdiara, IoannisKotsianidis, DimitriosMargaritis, AggelosGoutzouvelidis, Anna Christoforidou, Costas Tsatalas& George Bourikas. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients. Ann Haematol 2009 Jul; 88(7): 629-32. 16.KotsianidisI, BouchliouI, NakouE, Spanoudakis E, MargaritisD, ChristophoridouAV, AnastasiadesA, TsigalouC, BourikasG, KaradimitrisA, TsatalasC.Kinetics, function and bone marrow traffickingof CD4+CD25highFoxp3+ regulatory T cells in Myelodysplastic Syndromes (MDS). Leukemia. Mar 2009;23:pp510-18. 17. Spanoudakis E, Hu M, Naresh K, Terpos E, Melo V, Reid A,Kotsianidis I, A. Rahemtulla A, Karadimitris A. Regulation of multiple myeloma survival and progression by CD1d.Blood; 12 Μαρ 2009;113:pp 2498-2507. 18.Avloniti A., Douda H., Tokmakidis S., Kortsaris A., Papadopoulou E. & Spanoudakis E. Acute effects of soccer training onwhite blood cells count in elite female patients. JSportPhysiolandPerformance. 2007; 2: 239-249. 19. E. Spanoudakis, C. Tsatalas.Hemopoiesis in Ph-negative Myeloproliferative disorders. Review Article. Current Stem Cell Research and Therapy. 2009 May;4(2): 154-60. 20.Christoforidou A, Pantelidou D, Anastasiadis A, Goutzouvelidis A, Margaritis D, Kotsianidis I, Spanoudakis E, Kaloutsi V, Bourikas G, Tsatalas C. Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative disorders resistant or intolerant to monotherapy. ActaHaematologica. Jan 2009;120(4): 195-8. 21. Kotsianidis I, Nakou E, Bouchliou I, Tzouvelekis A, Spanoudakis E, Steiropoulos P, Sotiriou I, Aidinis V, Margaritis D, Tsatalas C. and Bouros D. Global impairment of CD4+cd25+Foxp3+ T-Regulatory cells in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine. 2009 Jun 15; 179(12): 1121-30. 22. Tsatalas C, Chalkia P, Pantelidou D, Margaritis D, Bourikas G, Spanoudakis E. Pregnancy in β-thalassemia trait carriers: an uneventfull journey. ReviewArticle. Hematology. 2009 Oct;14(5):301-3. 23.Anastasiadis A, Margaritis D, Kotsianidis I, Spanoudakis E, Christoforidou A, Kostopoulos I, Tsatalas C. Pure red cell aplasia as first manifestation of splenic marginal zone lymphoma-successful treatment with rituximab: a case report.Cases J. 2009 Aug 18;2:6913. 24. Kotsianidis I, Goutzouvelidis A, Anastasiades A, Bouchliou I, Nakou E, Spanoudakis E, Christophoridou AV, Margaritis D, Bourikas G, Tsatalas C.Severe thrombocytopenia and fibrinolysis mimicking disseminated intravascular coagulation after rituximab infusion.Am J Hematol. 2010 Feb;85(2):146. 25. Spanoudakis E, Bazdiara I, Pantelidou D, Kotsianidis I, Papadopoulos V, Margaritis D, Xanthopoulidis G, Moustakidis E, Mantzourani S, Bourikas G, Tsatalas C.Dynamics of telomere's length and telomerase activity in Philadelphia
chromosome negative myeloproliferativeneoplasms.Leuk Res. 2011 Apr;35(4):459-64.
26.Hu M, Bassett JH, Danks L, Howell PG, Xu K, Spanoudakis E, Kotsianidis I, Boyde A, Williams GR, Horwood N, Roberts IA, Karadimitris A.Activated invariant NKT cells regulate osteoclast development and function.JImmunol. 2011 Mar 1;186(5):2910-7. 27.Bouchliou I, Miltiades P, Nakou E, Spanoudakis E, Goutzouvelidis A, Vakalopoulou S, Garypidou V, Kotoula V, Bourikas G, Tsatalas C, Kotsianidis I.Th17 and Foxp3(+) T regulatory cell dynamics and distribution in myelodysplasticsyndromes.ClinImmunol. 2011 Jun;139(3):350-9. 28. Vadikolia CM, Tsatalas C, Anagnostopoulos K, Trypsianis G, Pantelidou D, Bazdiara I, Anastasiadis A, Spanoudakis E, Kotsianidis I, Margaritis D, Kortsaris A, Bourikas G.Proteolytic matrix metallopeptidases and inhibitors in BCR-ABL1-negative myeloproliferative neoplasms: correlation with JAK2 mutation status.ActaHaematol. 2011;126(1):54-62. 29. Kotsianidis I, Nakou E, Spanoudakis E, Bouchliou I, Moustakidis E, Miltiades P, Vadikolia CM, Szydlo R, Karadimitris A, TsatalasC. The diagnostic value of CD1d expression in a large cohort of patients with B-cell chronic lymphoproliferativedisorders. Am J ClinPathol. 2011 Sep;136(3):400-8. 30. Courcoutsakis N, Spanoudaki A, Maris TG, Astrinakis E, Spanoudakis E, Tsatalas C, PrassopoulosP.Perfusion parameters analysis of the vertebral bone marrow in patients with Ph¹⁻ chronic myeloproliferative neoplasms (Ph(neg) MPN): a dynamic contrast-enhanced MRI (DCE-MRI) study.JMagnReson Imaging. 2012 Mar;35(3):696- 702. 31. Kotsianidis I, Spanoudakis E, Nakou E, Miltiades P, Margaritis D, Tsatalas C, Tzouvelekis A, OikonomouA.Hypomethylating therapy and autoimmunity in MDS: An enigmatic relationship.Leuk Res. 2012 Apr;36(4):e90-2. 32. Nakou E, Babageorgakas P, Bouchliou I, Tziakas DN, Miltiades P, Spanoudakis E, Margaritis D, Kotsianidis I, Stakos DA. Statin-Induced Immunomodulation Alters Peripheral Invariant Natural Killer T-cell Prevalence in Hyperlipidemic Patients Cardiovasc Drugs Ther. 2012 Mar 24.
Alliance CompleteCare Future Formulary Change File CMS FORMULARY ID: 13348 EFFECTIVE DATE: 6/1/2013 DRUG NAME DILANTIN 50 MG ORAL CHANGE DESCRIPTION BRAND DELETION, ADD FRF GENERIC REASON DESCRIPTION REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT. OTHER POSSIBLE DRUGS Alliance CompleteCare Future Formulary
FREQUENTLY ASKED QUESTIONS Who is the Camp Director? Jeff Mackin, Education Director What are the qualifications of the counselors? What are their certifications? Have they had background checks and been fingerprinted? Are they local residents or from another state? Staff is certified in CPR and First Aid. Most of the IGFA Educational Staff have or are attaining a Bachelors or Maste